CRISPR Therapeutics has hit an 80 or higher Relative Strength Rating, a significant improvement from its previous score of 76. This exclusive rating from Investor’s Business Daily tracks share price action and is based on a scale from 1 (worst) to 99 (best). The company’s stock price has also seen a jump, with the RS rating upgrade showing improving technical performance.
The increase in CRISPR Therapeutics’ Relative Strength Rating indicates that investors have become more optimistic about its future prospects. This could be a positive sign for the company’s stock price and investors who hold shares.
Source: https://www.investors.com/ibd-data-stories/stocks-showing-rising-market-leadership-crispr-therapeutics-earns-82-rs-rating